These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19731464)

  • 1. Clinical roundtable monograph. Choosing an appropriate therapy for lower-risk MDS in the community setting.
    Lyons RM
    Clin Adv Hematol Oncol; 2009 Jul; 7(7):S5-7. PubMed ID: 19731464
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical roundtable monograph. Overall survival and maintenance of MDS patients.
    Silverman LR
    Clin Adv Hematol Oncol; 2009 Jul; 7(7):S3-5. PubMed ID: 19708287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epigenetic therapy in myelodysplastic syndromes].
    Maki K; Mitani K
    Rinsho Ketsueki; 2011 Jul; 52(7):438-46. PubMed ID: 21821974
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
    Issa JP
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S24-9. PubMed ID: 16341237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 6. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
    Lübbert M; Kuendgen A
    Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
    [No Abstract]   [Full Text] [Related]  

  • 8. Decitabine in myelodysplastic syndromes.
    Saba HI; Wijermans PW
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation therapy for myelodysplastic syndrome.
    Hofmann WK; Koeffler HP
    Clin Cancer Res; 2002 Apr; 8(4):939-41. PubMed ID: 11948096
    [No Abstract]   [Full Text] [Related]  

  • 10. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
    Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent experience with decitabine in MDS.
    Kantarjian HM
    Clin Adv Hematol Oncol; 2007 Feb; 5(2):140. PubMed ID: 17344803
    [No Abstract]   [Full Text] [Related]  

  • 12. [Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature].
    Gao Y; Ping B; Zhou S
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Feb; 32(2):280-2. PubMed ID: 22381778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine.
    Pitako JA; Haas PS; Van den Bosch J; Müller-Berndorff H; Kündgen A; Germing U; Wijermans PW; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():25-31. PubMed ID: 16292666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
    Tohyama K
    Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasia.
    Schaefer HE; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():67-79. PubMed ID: 16308721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative dosing schedules for methylation inhibitors in MDS treatment.
    Frame D
    Manag Care; 2009 Nov; 18(11 Suppl 9):15-9; discussion 19-20. PubMed ID: 20085112
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug therapy for myelodysplastic syndrome: building evidence for action.
    Tefferi A; Letendre L
    Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501
    [No Abstract]   [Full Text] [Related]  

  • 18. Myelodysplasia, megakaryocytes, and methylation.
    Steensma DP
    Leuk Res; 2004 Aug; 28(8):775-6. PubMed ID: 15203274
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
    Yee KW; Jabbour E; Kantarjian HM; Giles FJ
    Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
    Fenaux P
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.